News and Trends 10 Jan 2020 Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B The French company Eyevensys has raised €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness. The Series B round was led by the Boehringer Ingelheim Venture Fund. New investors to Eyevensys in this round included […] January 10, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2020 French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy drug to phase I. The UK VC firm Medicxi and the returning French VC investor Advent France Biotechnology contributed to the round. Alderaan, whose name was inspired by a fictional planet in the Star Wars movies, will use part of […] January 9, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2020 €5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2020 Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […] January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 18 Dec 2019 Truffle Capital Raises €250M Fund to Launch Life Science Startups The French VC firm Truffle Capital has closed a fund worth €250M with a mission to nurture companies specializing in medical devices and robotics. The fund, named BioMedTech, will be used to create around 12 companies, with a focus on French startups. The majority of the fund, around 60%, came from French investors and the […] December 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2019 Transgene’s Cancer Vaccine Abandoned after Phase II Fail French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […] December 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […] December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 3 Dec 2019 Sensorion’s Vertigo Drug Abandoned in Phase II A small molecule drug developed by the French company Sensorion has proven ineffective in a phase IIb trial for the treatment of a rare vertigo condition, leading the company to close down the development of the drug. The phase IIb trial tested Sensorion’s lead drug in 105 patients with the rare condition acute unilateral vestibulopathy, […] December 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2019 €31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes The French biotech Diabeloop has raised €31M to launch an artificial pancreas device designed to automatically control the blood glucose levels of type 1 diabetes patients. According to Diabeloop, this is the biggest Series B round raised by a European company developing therapies that use artificial intelligence. The round was led by the French family […] December 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 29 Nov 2019 MedinCell Granted €17M to Develop Cheap Long-Acting Contraception The French company MedinCell has received a €17.3M ($19M) grant from the Bill and Melinda Gates Foundation to advance its long-acting contraceptive implant to human trials. The grant is a follow-on to a €3.2M endowment from the Gates Foundation in 2017 to fuel early preclinical development of the implant. The additional funds will help MedinCell […] November 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 20 Nov 2019 €39M Series B to Fund Biopolymers for Surgery and Implants The French company Tissium has raised a €38.8M Series B round to fund the development of polymers that can be used to repair blood vessels and nerves. Contributing to the round were newcomers to Tissium such as the European Investment Fund and returning investors such as the investment bank Bpifrance and French life sciences […] November 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2019 US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […] November 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email